Cetin G, Totuk O, Erturk Cetin O, Demir S, Sahin S
BMC Neurol. 2025; 25(1):62.
PMID: 39948478
PMC: 11823226.
DOI: 10.1186/s12883-025-04070-2.
Palmer A, Hamann T, Liese J, Muller B, Kropp P, Jurgens T
Front Neurol. 2024; 15:1343093.
PMID: 38419716
PMC: 10900232.
DOI: 10.3389/fneur.2024.1343093.
Sharpless L, Kesselheim A, Orr S, Darrow J
Neurology. 2023; 101(10):e989-e1000.
PMID: 37438124
PMC: 10491441.
DOI: 10.1212/WNL.0000000000207544.
Yalinay Dikmen P, Ozge A, Martelletti P
Heliyon. 2023; 9(5):e16187.
PMID: 37251845
PMC: 10220237.
DOI: 10.1016/j.heliyon.2023.e16187.
Hu B, Li G, Li X, Wu S, Yu T, Li X
J Headache Pain. 2022; 23(1):90.
PMID: 35896988
PMC: 9330971.
DOI: 10.1186/s10194-022-01458-0.
Reliability and Validity of Turkish Version of Headache Impact Test (HIT-6) in Patients with Migraine.
Yalinay Dikmen P, Bozdag M, Gunes M, Kosak S, Tasdelen B, Uluduz D
Noro Psikiyatr Ars. 2021; 58(4):300-307.
PMID: 34924791
PMC: 8665287.
DOI: 10.29399/npa.24956.
The Altered Functional Connectivity With Pain Features Integration and Interaction in Migraine Without Aura.
Tian Z, Yin T, Xiao Q, Dong X, Yang Y, Wang M
Front Neurosci. 2021; 15:646538.
PMID: 33746709
PMC: 7969893.
DOI: 10.3389/fnins.2021.646538.
Systematic review of outcomes and endpoints in acute migraine clinical trials.
Houts C, McGinley J, Nishida T, Buse D, Wirth R, Dodick D
Headache. 2021; 61(2):263-275.
PMID: 33611818
PMC: 7986374.
DOI: 10.1111/head.14067.
Health technology assessment for the acute and preventive treatment of migraine: A position statement of the International Headache Society.
Diener H, Ashina M, Durand-Zaleski I, Kurth T, Lanteri-Minet M, Lipton R
Cephalalgia. 2021; 41(3):279-293.
PMID: 33472427
PMC: 7961634.
DOI: 10.1177/0333102421989247.
Concurrent brain structural and functional alterations in patients with migraine without aura: an fMRI study.
Li Z, Zhou J, Lan L, Cheng S, Sun R, Gong Q
J Headache Pain. 2020; 21(1):141.
PMID: 33287704
PMC: 7720576.
DOI: 10.1186/s10194-020-01203-5.
Effectiveness and tolerability of repetitive transcranial magnetic stimulation for preventive treatment of episodic migraine: a single-centre, randomised, double-blind, sham-controlled phase 2 trial (Magnet-EM).
Mohamad Safiai N, Amir N, Basri H, Inche Mat L, Hoo F, Yusof Khan A
Trials. 2020; 21(1):923.
PMID: 33176870
PMC: 7657359.
DOI: 10.1186/s13063-020-04832-y.
Impact of galcanezumab on total pain burden: findings from phase 3 randomized, double-blind, placebo-controlled studies in patients with episodic or chronic migraine (EVOLVE-1, EVOLVE-2, and REGAIN trials).
Ailani J, Scott Andrews J, Rettiganti M, Nicholson R
J Headache Pain. 2020; 21(1):123.
PMID: 33069214
PMC: 7568830.
DOI: 10.1186/s10194-020-01190-7.
Benefits Beyond Headache Days With OnabotulinumtoxinA Treatment: A Pooled PREEMPT Analysis.
Diener H, Dodick D, Lipton R, Manack Adams A, DeGryse R, Silberstein S
Pain Ther. 2020; 9(2):683-694.
PMID: 33026631
PMC: 7648806.
DOI: 10.1007/s40122-020-00198-w.
The Impact of OnabotulinumtoxinA vs. Placebo on Efficacy Outcomes in Headache Day Responder and Nonresponder Patients with Chronic Migraine.
Silberstein S, Diener H, Dodick D, Manack Adams A, DeGryse R, Lipton R
Pain Ther. 2020; 9(2):695-707.
PMID: 33026630
PMC: 7648816.
DOI: 10.1007/s40122-020-00199-9.
Ubrogepant, an Acute Treatment for Migraine, Improved Patient-Reported Functional Disability and Satisfaction in 2 Single-Attack Phase 3 Randomized Trials, ACHIEVE I and II.
Dodick D, Lipton R, Ailani J, Halker Singh R, Shewale A, Zhao S
Headache. 2020; 60(4):686-700.
PMID: 32073660
PMC: 7155006.
DOI: 10.1111/head.13766.
The crossover design for migraine preventives: an analyses of four randomized placebo-controlled trials.
Jenssen A, Stovner L, Tronvik E, Sand T, Helde G, Gravdahl G
J Headache Pain. 2019; 20(1):119.
PMID: 31881823
PMC: 6935071.
DOI: 10.1186/s10194-019-1067-z.
Acupuncture versus propranolol in migraine prophylaxis: an indirect treatment comparison meta-analysis.
Chen Y, Li J, Chen M, Yue L, She T, Zheng H
J Neurol. 2019; 267(1):14-25.
PMID: 31435770
DOI: 10.1007/s00415-019-09510-x.
Why is the therapeutic effect of acute antimigraine drugs delayed? A review of controlled trials and hypotheses about the delay of effect.
Tfelt-Hansen P, Messlinger K
Br J Clin Pharmacol. 2019; 85(11):2487-2498.
PMID: 31389059
PMC: 6848898.
DOI: 10.1111/bcp.14090.
Psychological therapies for the prevention of migraine in adults.
Sharpe L, Dudeney J, de C Williams A, Nicholas M, McPhee I, Baillie A
Cochrane Database Syst Rev. 2019; 7:CD012295.
PMID: 31264211
PMC: 6603250.
DOI: 10.1002/14651858.CD012295.pub2.
The first comparative double-blind trial on efficacy and safety of ergotamine based five-component combination and sumatriptan in migraine without aura.
Miljkovic S, Smajlovic D, Tiric Campara M, Jurina R, Duranovic Vinkovic L, Jankovic S
Hippokratia. 2019; 22(1):17-22.
PMID: 31213753
PMC: 6528700.
